FIELD: medicine.
SUBSTANCE: invention can be used to treat an infection caused by the hepatitis C virus (HCV). A composition for HCV infection treatment of by the RNAi mechanism consists of complexes of lipopeptides of the OrnGlu (C16H33)2 composition, serving as a carrier, and siRNA molecules represented by 5'-AAAUCUCCAGGCAUUGAGCtt-3' (SEQ ID NO 1). Composition application on a transplantable cell culture of human hepatoma Huh-7, expressing the subgenomic replicon of HCV, causes a significant decrease in viral replicon expression by 20%.
EFFECT: high bioavailability with subcutaneous administration of the composition.
2 cl, 8 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF FORMATION OF VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C | 2011 |
|
RU2461834C1 |
| THERAPEUTIC AGENT FOR TREATING VIRAL HEPATITIS C | 2014 |
|
RU2568872C1 |
| USE OF CYTOKINE OF INTERLEUKIN-6 FAMILY FOR MAKING COMPOSITION FOR JOINT ADMINISTRATION WITH INTERFERON-ALPHA | 2006 |
|
RU2413529C2 |
| DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
| METHOD FOR PREDICTING THE ABSENCE OF REGRESS OF HEPATIC FIBROSIS IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723387C1 |
| METHODS FOR IMPROVING PHARMACOKINETICS | 2010 |
|
RU2591830C2 |
| METHOD OF TREATING VIRAL HEPATITIS C | 2012 |
|
RU2496512C1 |
| ANTIVIRAL COMPOUND OF MULTIPLE ACTION, ITS COMPOSITION AND METHOD OF TREATING VIRAL DISEASES | 2012 |
|
RU2597150C2 |
| PEGYLATED INTERFERON LAMBDA WITH HIGH BIOACCESSABILITY IN ORAL USE AND METHOD FOR PRODUCTION THEREOF | 2017 |
|
RU2678332C1 |
| IMMUNOBIOLOGICAL AGENT TO ENHANCE CELLULAR RESPONSE AGAINST HEPATITIS C VIRUS | 2023 |
|
RU2811136C1 |
